中國化學(601117.SH):全資子公司中標約115億元幾內亞Mavcard鋁土礦配套氧化鋁精煉廠項目
格隆匯11月15日丨中國化學(601117.SH)公佈,近日,公司全資子公司中國化學工程第七建設有限公司收到Mavcard英國有限公司幾內亞Mavcard鋁土礦配套氧化鋁精煉廠項目的中標通知,金額約為18億歐元(摺合人民幣約為115億元)。
本項目位於幾內亞拉貝省圖蓋和庫比亞區,主要為幾內亞共和國拉貝省的Mavcard鋁土礦項目開發並建設年產150-200萬噸配套氧化鋁精煉廠。本項目中標金額約佔本公司經審計2020年營業收入的10.52%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.